Mydecine Innovations Group Inc.
MYCO
CNSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -39.23% | -65.81% | -83.07% | -64.13% | -55.99% |
| Depreciation & Amortization | -- | -- | -- | -100.00% | -95.43% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 82.09% | -2.41% | -83.38% | -59.81% | -61.82% |
| Operating Income | -82.09% | 2.41% | 83.38% | 59.81% | 61.82% |
| Income Before Tax | -65.51% | -4.05% | 90.26% | -95.66% | 62.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -65.51% | -4.05% | 90.26% | -95.66% | 62.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -65.51% | -4.05% | 90.26% | -500.88% | 65.36% |
| EBIT | -82.09% | 2.41% | 83.38% | 59.81% | 61.82% |
| EBITDA | -82.07% | 2.37% | 83.42% | 59.75% | 61.43% |
| EPS Basic | 23.13% | 57.18% | 96.64% | -202.23% | 88.50% |
| Normalized Basic EPS | 22.92% | 57.08% | 91.35% | 75.21% | 85.98% |
| EPS Diluted | 23.13% | 57.18% | 96.64% | -202.23% | 88.50% |
| Normalized Diluted EPS | 22.92% | 57.08% | 91.35% | 75.21% | 85.98% |
| Average Basic Shares Outstanding | 114.81% | 143.26% | 189.87% | 292.11% | 201.44% |
| Average Diluted Shares Outstanding | 114.81% | 143.26% | 189.87% | 292.11% | 201.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
